HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: EJE-08-0213v1 EJE-08-0213v2 159/1/1    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Lancellotti, P. Articles by Beckers, A. PubMed PubMed Citation Articles by Lancellotti, P. Articles by Beckers, A.

Cabergoline and the risk of valvular lesions in endocrine disease

P Lancellotti, Department of Cardiology, CHU de Liege, Liege, Belgium
E Livadariu, Service d'Endocrinologie, CHU de Liege, Liege, Belgium
M Markov, Department of Cardiology, CHU de Liege, Liege, Belgium
A Daly, Service d'Endocrinologie, CHU de Liege, Liege, Belgium
M Burlacu, Service d'Endocrinologie, CHU de Liege, Liege, Belgium
D Betea, Service d'Endocrinologie, CHU de Liege, Liege, Belgium
L Pierard, Department of Cardiology, CHU de Liege, Liege, Belgium
A Beckers, Service d'Endocrinologie, CHU de Liege, Liege, Belgium

Correspondence: Albert Beckers, Email: albert.beckers{at}chu.ulg.ac.be

Abstract

Aims: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown.

Methods and Results: We performed a cross-sectional, case-control echocardiographic study to assess valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from 12-228 months, with a cumulative dose of 18-1718 mg. Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two cabergoline-treated subjects patients had moderate mitral regurgitation; there was no relationship between cabergoline dose and the presence or severity of mitral valve regurgitation P=NS). Mitral valve tenting area was significantly greater in the cabergoline group as compared to the control subjects (P=0.03). Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction.

Conclusion: No significantly increased risk of clinically-relevant cardiac valve disorders were found in subjects treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to cabergoline appears to be safe during low-dose long term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded.

This article has been cited by other articles:

				S. Droogmans, B. Cosyns, and G. Van Camp Pergolide and valvular heart disease: the lower the better? Eur J Echocardiogr, July 18, 2008; (2008) jen202v1. [Full Text] [PDF]